Lastly, bevacizumab, an anti-VEGF antibody, was given in combination with capecitabine to 10 patients with locally advanced or metastatic disease after treatment with mitotane and at least one line of chemotherapy led to no meaningful clinical benefit was observed.[68] These results document the limited clinical efficacy of these VEGF and VEGFR inhibitors for the treatment of ACC. This evidence concerns the gene VEGFA and adrenal cortex carcinoma.